Secukinumab: A Review in Psoriatic Arthritis

Blair, Hannah A.

doi:10.1007/s40265-021-01476-3

Cited by 37 publications

(32 citation statements)

References 54 publications

(214 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Discussion of the use of secukinumab in other approved indications (i.e. adult plaque psoriasis [10], psoriatic arthritis [11,12], ankylosing spondylitis [13,14], and non-radiographic axial spondyloarthritis) is outside the scope of this article.…”

Section: Clinical Responsementioning

confidence: 99%

Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis

Blair

2021

Pediatr Drugs

Self Cite

View full text Add to dashboard Cite

Subcutaneous secukinumab (Cosentyx ® ) is a recombinant, fully human, immunoglobulin (Ig) G1κ monoclonal antibody targeted against interleukin (IL)-17A, a proinflammatory cytokine involved in the pathogenesis of psoriasis. Secukinumab is approved in the EU and the USA for the treatment of moderate to severe plaque psoriasis in pediatric patients aged ≥ 6 years. In pivotal phase III trials in pediatric patients aged 6 to < 18 years, both low (75-150 mg) and high (75-300 mg) doses of secukinumab were significantly better than placebo and numerically better than etanercept at week 12 in terms of the proportion of patients achieving ≥ 75% improvement from baseline in Psoriasis Area and Severity Index and significantly better than placebo and etanercept in terms of the proportion of patients achieving an Investigator's Global Assessment score of 0 or 1. The clinical efficacy of secukinumab observed during the first 12 weeks of treatment was maintained over the longer term. Treatment with secukinumab improved health-related quality of life and was generally well tolerated. In conclusion, secukinumab represents a valuable new addition to the limited treatment options available for children and adolescents with moderate to severe plaque psoriasis. Plain Language SummaryPlaque psoriasis is a chronic, inflammatory skin condition that can have a negative impact on the quality of life of affected children and their families. Compared with the expanding treatment options for adults with plaque psoriasis, the number of approved medications for pediatric plaque psoriasis is relatively low. Subcutaneous secukinumab (Cosentyx ® ) is one of several targeted biologic agents that have recently been approved for treating plaque psoriasis in pediatric patients. Secukinumab binds to IL-17A and inhibits the release of proinflammatory cytokines and chemokines. Treatment with secukinumab provided fast and durable skin clearance and continuous improvements in health-related quality of life in children and adolescents aged 6 to < 18 years with moderate to severe plaque psoriasis. The benefits of secukinumab were maintained over the longer term and the drug was generally well tolerated. With a convenient 4-weekly maintenance dosing regimen and the option of caregiver administration, secukinumab is a valuable option for the treatment of moderate to severe pediatric plaque psoriasis.

show abstract

Section: Clinical Responsementioning

confidence: 99%

Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis

Blair

2021

Pediatr Drugs

Self Cite

View full text Add to dashboard Cite

show abstract

“…Brodalumab Siliq™ is indicated for moderate to severe plaque psoriasis [ 73 ]. While this drug acts by antagonizing the IL-17A Receptor, Cosentyx™ and Taltz™ antagonize the pro-inflammatory cytokine IL-17A, which plays a role in psoriasis and Psa [ 67 , 69 ]. Guselkumab Tremfya™, used for the treatment of psoriasis and Psa, is an antibody that blocks the activity of two interleukins (IL-23, IL-17A) that are overexpressed in these diseases [ 71 ].…”

Section: Autoimmune Diseasesmentioning

confidence: 99%

Trends and Perspectives of Biological Drug Approvals by the FDA: A Review from 2015 to 2021

et al. 2022

View full text Add to dashboard Cite

Despite belonging to a relatively new class of pharmaceuticals, biological drugs have been used since the 1980s, when they brought about a breakthrough in the treatment of chronic diseases, especially cancer. They conquered a large space in the pipeline of the pharmaceutical industry and boosted the innovation portfolio and arsenal of therapeutic compounds available. Here, we report on biological drug approvals by the US Food and Drug Administration (FDA) from 2015 to 2021. The number of drugs included in this class grew over this period, totaling 90 approvals, with an average of 13 authorizations per year. This figure contrasts with previous periods, which registered between 2 and 8 approvals per year. We highlight the great potential and advantages of biological drugs. In this context, these therapeutics show high efficacy and high selectivity, and they have brought about a significant increase in patient survival and a reduction of adverse reactions. The development and production of biopharmaceuticals pose a major challenge because these processes require cutting-edge technology, thereby making the drugs very expensive. However, we believe that, in the near future, biological medicines will be more accessible and new drugs belonging to this class will become available as new technologies emerge. Such advances will enhance the production of these biopharmaceuticals, thereby making the process increasingly profitable and less expensive, thereby bringing about greater availability of these drugs.

show abstract

“…У пациентов с аксиальным поражением и сопутствующим тяжелым псориазом использование секукинумаба может рассматриваться в качестве эффективного варианта терапии [35,36]. В то же время следует отметить, что применение ингибиторов ИЛ-17А ограничено при наличии воспалительного заболевания кишечника из-за риска его обострения.…”

Section: ревматологияunclassified

Psoriatic Arthritis: Pathogenetic Justification of Current Therapeutic Approaches

Korotaeva¹,

Scientific²,

Moscow³

2021

View full text Add to dashboard Cite

Objective of the Review: To analyse and summarise information on the pathogenesis of psoriatic arthritis (PsA); to discuss therapeutic targets, actual and long-term drug therapy strategies for this disease. Key Points. PsA pathogenesis is still a matter of argument; some of its mechanisms are still studied poorly. It is assumed that, in patients with genetic predisposition, the disease is triggered by the environmental factors, dysbiosis, infections, stress, that can cause and maintain aberrant activation of the innate and adaptive immune system. We found out that increased expression of such cytokines as IL-6, TNF-α and IL-17A causes synovitis; activates neoangiogenesis, bone resorption and erosion; leads to destruction and inflammation of cartilage as a result of induction of several molecular paths in synovial fibroblasts and macrophages, endothelial cells, osteoblasts, osteoclasts, cartilage cells, and immune cells. Taking into account available information on pathogenic mechanisms of PsA and psoriasis, we have developed several drugs targeting cells, cytokines or other mediators, playing a central role in the pathogenesis of the disease. Conclusion. Currently, treatment of psoriasis and PsA involves the use of traditional basic synthetic anti-inflammatory medicines, genetically engineered biological agents, and target oral synthetic medications, particularly phosphodeisterase-4 inhibitors and Janus kinase inhibitors, a majority of which can treat the entire range of skin and bone manifestations of the disease. Taking into account the varying PsA phenotype, comorbidities and a wide range of medicinal products that can be used by medical professionals, a majority of authors are of the opinion that it is necessary to improve the algorithms of individual approaches to the management of each patient. Keywords: psoriatic arthritis; immunopathogenesis; genetically engineered biological agents.

show abstract

Secukinumab: A Review in Psoriatic Arthritis

Cited by 37 publications

References 54 publications

Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis

Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis

Trends and Perspectives of Biological Drug Approvals by the FDA: A Review from 2015 to 2021

Psoriatic Arthritis: Pathogenetic Justification of Current Therapeutic Approaches

Contact Info

Product

Resources

About